Log in

Zogenix Stock Price, News & Analysis (NASDAQ:ZGNX)

$41.04
+0.83 (+2.06 %)
(As of 10/14/2019 06:49 AM ET)
Today's Range
$40.13
Now: $41.04
$41.50
50-Day Range
$39.18
MA: $42.41
$51.89
52-Week Range
$33.43
Now: $41.04
$56.50
Volume435,541 shs
Average Volume404,137 shs
Market Capitalization$1.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.94
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc and changed its name to Zogenix, Inc in August 2006. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.82 million
Book Value$12.46 per share

Profitability

Net Income$-123,910,000.00

Miscellaneous

Employees90
Market Cap$1.82 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.


Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.89) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.06. The firm earned $1.07 million during the quarter, compared to analysts' expectations of $15 million. During the same period last year, the company posted ($0.83) EPS. View Zogenix's Earnings History.

When is Zogenix's next earnings date?

Zogenix is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Zogenix.

What price target have analysts set for ZGNX?

10 brokerages have issued 1-year target prices for Zogenix's stock. Their forecasts range from $48.00 to $71.00. On average, they anticipate Zogenix's share price to reach $59.89 in the next year. This suggests a possible upside of 45.9% from the stock's current price. View Analyst Price Targets for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. Northland Securities analysts commented, "We note that 1504 demonstrated 63% and 54% reductions in mean monthly convulsive seizure frequency, versus comparator arms that excluded or included stiripentol therapy, respectively. FINTEPLA was also shown to significantly extend seizure free intervals to ~1 month, with an exceptionally high response rate >70%." (7/8/2019)
  • 2. Mizuho analysts commented, "We gave consideration to (70% PoS). DCF: We assumed a 13% discount rate and a terminal value of 4.5x our estimated 2028 FCF of $861 mil. EV/Sales: we apply a 8x multiple to discounted 2025 sales of $352 mil. the U.S. market, we assume 4Q19 launch and peak market share of 75% (among new therapies) in 2028, equivalent to $526mn in peak sales; for EU and Japan, we assume late 2021 and late 2022 launches. For LGS, we project peak market penetration of 14% in 2028 in the U.S and PoS adjusted sales of $463mn." (3/19/2019)
  • 3. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (2/23/2019)

Has Zogenix been receiving favorable news coverage?

News coverage about ZGNX stock has trended negative recently, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zogenix earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Zogenix.

Are investors shorting Zogenix?

Zogenix saw a decrease in short interest in September. As of September 15th, there was short interest totalling 8,340,000 shares, a decrease of 5.8% from the August 15th total of 8,850,000 shares. Based on an average daily trading volume, of 583,400 shares, the days-to-cover ratio is presently 14.3 days. Approximately 19.6% of the company's stock are sold short. View Zogenix's Current Options Chain.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals PLC- (GWPH), Vanda Pharmaceuticals (VNDA), QUALCOMM (QCOM), Celgene (CELG), Gilead Sciences (GILD), Southwest Airlines (LUV), Alibaba Group (BABA), AbbVie (ABBV), Canopy Growth (CGC) and NVIDIA (NVDA).

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $41.04.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.82 billion and generates $9.82 million in revenue each year. The company earns $-123,910,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Zogenix employs 90 workers across the globe.View Additional Information About Zogenix.

What is Zogenix's official website?

The official website for Zogenix is http://www.zogenix.com/.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  718
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Gap Up Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel